Rivaroxaban 2.5 mg Tablet PCD Franchise in Mumbai

Anti-Coagulant Medicine Supplier in Delhi

Cardiovascular Tablet Distributor in Chennai

Thrombosis Prevention Pharma Franchise in Pune

Rivaroxaban Tablet Stockist in Kolkata
Anti-Coagulant Therapy Tablet Export & Manufacturing in Hyderabad

Home/Products /rivaroxaban-micronized-2-5mg-tablet

About the Product

Description


Rivafoli 2.5 Tablet contains Rivaroxaban 2.5 mg, a direct oral anticoagulant (DOAC) that helps prevent blood clot formation and reduce the risk of stroke in patients with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE).

Belonging to the cardiology and anti-coagulant segment, Rivaroxaban is widely prescribed for both prophylaxis and treatment of thromboembolic events. Its oral administration provides convenience and adherence compared to traditional injectable anticoagulants.

The medicine works by selectively inhibiting Factor Xa, which prevents the conversion of prothrombin to thrombin, thereby reducing clot formation and maintaining normal blood flow. This mechanism is vital for cardiovascular patients at risk of recurrent events.

For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Rivafoli 2.5 Tablet offers a profitable B2B opportunity, catering to hospitals, cardiology clinics, and specialty pharmacies across India. Its therapeutic importance ensures consistent demand and high market value.

Common side effects include bleeding, bruising, or minor nosebleeds. Rare but serious effects may include gastrointestinal bleeding, intracranial hemorrhage, or severe allergic reactions. Seek immediate medical attention if you experience prolonged bleeding, black stools, or severe dizziness.

Rivafoli 2.5 Tablet is indicated for the prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). It may also be prescribed alongside low-dose aspirin to reduce the risk of heart attack, stroke, or blood clots.

Take Rivafoli 2.5 Tablet exactly as prescribed, preferably at the same time each day. Do not stop or change the dose without consulting your doctor, as this increases the risk of blood clots. Inform your physician if you have kidney or liver disease, a history of bleeding disorders, or are on other blood-thinning medications.

Store Rivafoli 2.5 Tablet in a cool, dry place below 25°C, away from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Rivaroxaban Micronized 2.5mg Tablet in the PCD pharma franchise market?

Rivaroxaban Micronized 2.5mg Tablet has strong demand in the cardiology, vascular care, and anticoagulant therapy segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on cardiovascular and specialty medicine portfolios.

Why should medical distributors include Rivaroxaban Micronized 2.5mg Tablet in their product range?

Medical distributors and agencies can benefit from growing demand for thrombotic disorder prevention and cardiovascular risk management under specialist supervision. Rivaroxaban Micronized 2.5mg is an oral anticoagulant (Factor Xa inhibitor) used in cardiovascular and vascular care Commonly prescribed for the prevention of blood clot-related complications in selected patients with cardiovascular and peripheral arterial diseases, as advised by healthcare professionals Helps reduce the risk of thrombotic events by inhibiting Factor Xa, an important component of the blood clotting process Micronized formulation is designed to support effective absorption and consistent therapeutic performance Oral tablet formulation provides convenient administration for long-term treatment plans under medical supervision Requires careful patient selection, monitoring, and adherence to prescribed therapy due to bleeding-related risks Frequently utilized in cardiology clinics, vascular care centers, hospitals, and specialty healthcare facilities Widely prescribed by cardiologists, vascular specialists, and internal medicine physicians This strengthens a comprehensive cardiovascular and anticoagulant therapy portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for this product?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Rivaroxaban Micronized 2.5mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for this product?

Wholesalers and medical agencies benefit from strong prescription demand, long-term patient usage, repeat purchases, specialty healthcare market opportunities, reliable supply chain support, and attractive margins in the cardiovascular care segment.

How can I become a distributor or franchise partner for this product?

Interested distributors, stockists, and wholesalers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.